Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Reexamination Certificate
2007-05-22
2007-05-22
Nashed, Nashaat T. (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
C435S320100, C530S384000, C536S023100
Reexamination Certificate
active
10407123
ABSTRACT:
Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence.
REFERENCES:
patent: 4359049 (1982-11-01), Redl et al.
patent: 4501731 (1985-02-01), Tishkoff et al.
patent: 4735616 (1988-04-01), Eibl et al.
patent: 5460950 (1995-10-01), Barr et al.
patent: 5597799 (1997-01-01), Wolf
patent: 5635481 (1997-06-01), Wolf
patent: 5858658 (1999-01-01), Haemmerle et al.
patent: 6210929 (2001-04-01), Schlokat et al.
patent: 6562598 (2003-05-01), Himmelspach et al.
patent: 0 651 054 (1995-05-01), None
patent: 0 714 987 (1996-06-01), None
patent: 0 775 750 (1997-05-01), None
patent: WO 94/29370 (1994-12-01), None
Verma and Somia, Gene therapy—promises, problems, and prospects (1997) Nature vol. 389, pp. 239-242.
Anderson, W. French, Human Gene Therapy. (1998) Nature, ol. 392, pp. 25-30.
Romano et al. Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications, (2000) Stem Cells vol: 18, pp. 19-39.
Somia and Verma, Gene Therapy: Trials and Tribulations (2000) Nature Reviews, Genetics, vol. 1, pp. 91-99.
Seidah et al. Eukaryotic protein processing: endoproteolysis of precursor proteins, (1997) Curr. Opin. Biotechnol. vol. 8, pp. 602-607.
Beinfeld et al. Characterization of an Endoprotease from Rat Small Intestinal Mucosal Secretory Granules Which Generates Somatostatin-28 from Prosomatostatin by Cleavage after a Single Arginine Residue. (1989) J. Biol. Chem. vol. 264, No. 8, pp. 4460-4465.
Magklara et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhbitors. (2003) Biochem. Biophys. Res. Comm. vol. 307, pp. 948-955.
Bajaj, Satya P., et al.; Simultaneous Purification of Bovine Prothrombin and Factor X;The Journal of Biological Chemistry; Nov. 25, 1973; pp. 7729-7741; vol. 248, No. 22.
Barr, Philip J.; Mammalian Subtilisins: The Long-Sought Dibasic Processing Endoprotease;Cell; Jul. 12, 1991; pp. 1-3; vol. 66.
Clackson, Tim, et al.; General applications of PCR to gene cloning and manipulation;PCR A Practical Approach; 1991; pp. 187-214; Oxford University Press.
Eby, C.S., et al; Characterization of the Structure and Function of the Carboxy Terminal Peptide of Human Factor X;Blood; 1992; p 306a; vol. 80, Supp. 1; 1214.
Elsinger, F.; Laboratory Tests of Activated Prothrombin Complex Preparations;Activated Prothrombin Complex Concentrates Managing Hemophilia with Factor VIII Inhibitor; 1982; pp. 77-87.
Fair, Daryl S., et al.; Human Hepatoma Cells Secrete Single Chain Factor X, Prothrombin, and Antithrombin III;Blood; Jul. 1984; pp. 194-204; vol. 64, No. 1.
Fung, Marion R., et al.; Characterization of an almost full-length cDNA coding for human blood coagulation factor X;Proc. Natl. Acad. Sci. USA; Jun. 1985; pp. 3591-3595; vol. 82.
Giles, Alan R., et al.; A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo;British Journal of Haematology; 1988; pp. 491-497; vol. 69.
Gordon, Valery M.; et al.; Proteolytic Activation of Bacterial Toxins by Eukaryotic Cells Is Performed by Furin and by Additional Cellular Proteases;Infect. Immunol.; 1995; pp. 82-87; vol. 69.
Jesty, Jolyon, et al.; The Mechanism of Activation of Factor X: Kinetic Control of Alternative Pathways Leading to the Formation of Activated Factor X;The Journal of Biological Chemistry; Sep. 10, 1974; pp. 5614-5622; vol. 249, No. 17.
Leytus, Steven P., et al.; Gene for Human Factor X: A Blood Coagulation Factor Whose Gene Organization Is Essentially Identical with That of Factor IX and Protein C;Biochemistry; Sep. 25, 1986; pp. 5098-5102; vol. 25.
Mertens, Koen, et al.; Pathways in the Activation of Human Coagulation Factor X;Biochem. J.; 1980; pp. 647-658; vol. 185.
Messier, Terri, L.; Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X;Gene; 1991; pp. 291-294; vol. 99.
Moehring, Joan M., et al.; Strains of CHO-K1 Cells Resistant toPseudomonasExotoxin A and Cross-Resistant to Diphtherie Toxin and Viruses;Infection and ImmunitySep. 1983; pp. 998-1009; vol. 41, No. 3.
Morita, Takashi, et al.: Structural and functional characteristics of a proteolytically modified, “Gla domain-less” bovine factor X and Xa (des light chain residues 1-44);General Biochem; 1980, p. 219; vol. 92; 92:71374k.
Ngo, J. Thomas, et al.; Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox;The Protein Folding Problem and Tertiary Structure Prediction; 1994; Merz and LeGrand, editors, Birkhauser, Boston, Chapter 14, pp. 492-495.
Ohnishi, Yukano, et al.; A Furin-Defective Cell Line Is Able to Process Correctly the gp 160 of Human Immunodeficiency Virus Type 1;Journal of Virology; Jun. 1994; pp. 4075-4079; vol. 68, No. 6.
Pryzdial, Edward L.G., et al.; Autoproteolysis of Plasmin-mediated Cleavage of Factor Xao Exposes a Plasminogen Binding Site and Inhibits Coagulation;The Journal of Biological Chemistry; Jul. 12, 1996; pp. 16614-16620; vol. 271, No. 28.
Pryzdial, Edward W.G.; et al.; Kinetics of Blood Coagulation Factor Xao Autoproteolytic Conversion to Factor Xaβ;The Journal of Biological Chemistry; Jul. 12, 1996; pp. 16621-16626; vol. 271, No. 28.
Rehemtulla, Alnawaz, et al.; Preferred Sequence Requirements for Cleavage of Pro-von Willebrand Factor by Propeptide-Processing Enzymes;Blood; May 11, 1992; pp. 2349-2355, vol. 79, No. 9.
Rudolph, Amy E.; Expression, Purification, and Characterization of Recombinant Human Factor X;Protein Expression and Purification; 1997; pp. 373-378; vol. 10; Article No. PT970752.
Sherrill, G. Bradley, et al.; Inactivation of human blood coagulation factor X by chemical modification of gamma-carboxyglutamic acid residues;Enzymes; 1985; p. 239; vol. 102; 102:2489q.
Teng, Che-Ming, et al.; Production of Factor X and Factor Xa Variants with Thrombin, Acutin and by Autolysis;Thrombosis Research; 1981; pp. 213-220; vol. 22, No. 1/2.
Urlaub, Gail, et al.; Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity;Proc. Natl. Acad. Sci USA; Jul. 1980; pp. 4216-4220; vol. 77, No. 7.
Wallin, Reidar, et al.; Intracellular Proteolytic Processing of the Two-Chain Vitamin K-Dependent Coagulation FActor X;Thrombosis Research; 1994; pp. 395-403; vol. 73; No. 6.
Watzke, Herbert H., et al.; Factor X;Molecular Basis of Trhombosis and Hemostatsis; eds. Hight and Roberts; 1995; chapter 11, pp. 239-255.
Wells, James A.; Additivity of Mulaticnal Effects in Proteins;Biochemistry; Sep. 18, 1990; pp. 8509-8516; vol. 29, No. 3;7.
Wolf, David L., et al.; Design of Constructs for the Expression of Biologically Active Recombinant Human Factors X and Xa;The Journal of Biological Chemistry; Jul. 25, 1991; pp. 13726-13730; vol. 266, No. 21.
Original and a translation of 1stPreliminary Notice in Austrian Patent Application No. A 335/97-1, stamped received Sep. 29, 1997 by the Austrian Patent Office.
International Search Report for PCT/AT 98/00045. dated Jun. 3, 1998.
Fischer et al. “Structural Analysis of Recombinant von Willebrand Factor: Identification of hetero- and homo-dimers”,FEBS Lett., 1994, pp. 345-348, vol. 351.
Leytus, S. et al. “Characterization of cDNA coding for human factor X.”Proc. Natl. Acad. Sci. USA, Jun. 1984, pp. 3699-3702, vol. 81.
Himmelspach, M. et al. “Alteration of the Specificity of fX Activation by Substitution of Amino Acids Constituting its Activation Site”,XVII Congress of the International Society on Thrombosis and Haemostasis, 1999. p. 758.
Dorner Friedrich
Eibl Johann
Fisch Andreas
Himmelspach Michele
Schlokat Uwe
Baxter Aktiengesellschaft
Nashed Nashaat T.
Schnizer Holly
LandOfFree
Nucleic acids encoding factor X analogues having a modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding factor X analogues having a modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding factor X analogues having a modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3787595